Importance of the Gut Microbiome for Gastrointestinal Health
BioProphyl: Professor Dr. Dr. Malfertheiner, you have conducted extensive research on various gastroenterological diseases. Could you tell us about the significance of the gut microbiome for gastrointestinal health and its potential impact on gastrointestinal diseases?
Prof. Dr. Dr. h.c. Peter Malfertheiner: The gut microbiome plays a vital role in maintaining health – a balanced gut microbiota is crucial. Dysbiosis, or an imbalanced gut microbiota, can lead to diseases and disorders in the gastrointestinal tract. A balanced gut microbiome is essential not only for gut health but also has a significant impact on the health of the entire organism.
Numerous studies have shown that the microbiome significantly affects the liver and liver diseases, as well as metabolism and metabolic disorders. Today, functional gastrointestinal diseases are attributed to bidirectional disturbances of the gut-brain axis, also known as "Disorders of Gut Brain Axis." Since the microbiome is involved in this concept, the term "Microbiome Gut Brain Axis" has been coined.
Currently, major research initiatives are underway on the interaction between the digestive tract and the central nervous system, mental illnesses, and neurodegenerative diseases, including dementia.
Basic science findings are increasingly being translated into clinical practice through probiotic medicine approaches. The field is complex: a favorable composition of the gut microbiome interacts with the human organism in many ways and is shaped by factors such as lifestyle, diet, sufficient sleep, and regular exercise.
Impact on Chronic Inflammatory Bowel Diseases
BioProphyl: How has your research influenced the understanding of the role of the gut microbiome in chronic inflammatory bowel diseases like ulcerative colitis or Crohn's disease?
Prof. Dr. Dr. h.c. Peter Malfertheiner: The topic of IBD (inflammatory bowel diseases) and the microbiome is of great importance, and numerous studies are currently exploring various questions in this interaction.
In IBD, changes in the microbiome composition are evident, but the therapeutic modulation of the gut microbiome remains a secondary focus. Some studies with specific probiotics have shown positive results. The most impressive findings have come from faecal microbiota transplantation from healthy donors (faecal transplantation), with healing successes in a group of patients with ulcerative colitis.
Currently, the focus of IBD therapy is on immunomodulation. In the future, it may be possible to intervene in the disease process through the microbiome. Immunotherapies are currently the standard and market leaders, aiming to downregulate excessive immune responses. Specific dietary recommendations are complementary but not primarily therapeutic. In this context, the administration of trace elements and vitamins also plays an important role.
Challenges in Microbiome Analysis
BioProphyl: Could you tell us about the challenges in analyzing and influencing the gut microbiome in the context of therapeutic studies on inflammatory bowel diseases and pancreatic diseases?
Prof. Dr. Dr. h.c. Peter Malfertheiner: High-quality publications have shown changes in the microbiome. However, intervention studies that show us how to beneficially influence the gut microbiome in bowel and pancreatic diseases are still lacking.
Therefore, unfortunately, there is no concrete recommendation at present, although I see great potential in such a concept. A large gap remains between science and clinical practice that needs to be bridged. The hope lies in large intervention studies that demonstrate which combination of probiotics and specific dietary factors may be beneficial. Only when clinical studies show a positive effect of probiotics can their use in these diseases be recommended.
Today, we can perform microbiome analyses on stool samples based on precise, molecular gene sequencing technologies of the gut microbiome. This allows for personalized results but requires knowledge of factors such as medication use, lifestyle, diet, and existing diseases. It is important to evaluate the effects of individual treatment measures during follow-up.
In the future, it may be conceivable to conduct stool analyses in individuals and, depending on specific findings, create a personalized treatment plan that provides insight into both the clinical outcome and the microbiome composition over time. It would be desirable to learn what is appropriate in an individual approach to influence the microbiome to be as beneficial to health as possible—similar to how appropriate training and diet patterns exist for sports.
Helicobacter pylori and Gut Microbiome
BioProphyl: Regarding the research on Helicobacter pylori-associated stomach diseases: Are there indications that the gut microbiome is associated with these diseases?
Prof. Dr. Dr. h.c. Peter Malfertheiner: Helicobacter pylori (H. pylori) has the unique ability to survive the attack of stomach acid, colonise the stomach and dominate all other microbes that can only remain in the acidic stomach environment for a short time. Once H. pylori colonizes the stomach, it leads to chronic gastritis. As chronic atrophic gastritis progresses, gastric acid decreases, and the bactericidal effect is lost. Only then can other microbiota establish themselves in the stomach.
Helicobacter pylori always causes gastric mucosal inflammation and can lead to the development of stomach ulcers and gastric cancer.
In advanced stages of chronic gastritis, the microbiome in the stomach changes and also affects the microbial composition in lower sections of the digestive tract.
Diagnosis and Treatment of Reflux Disease
BioProphyl: What advances do you see in the diagnosis and treatment of gastroesophageal reflux disease, and how could the gut microbiome play a role?
Prof. Dr. Dr. h.c. Peter Malfertheiner: Gastroesophageal reflux disease (GERD) is an inflammation of the esophagus caused by a pathologically impaired anti-reflux barrier. Increased acid reflux into the esophagus leads to symptoms such as heartburn and injuries to the esophageal mucosa (erosions).
The microbiome, according to current knowledge, does not play a primary role in GERD. However, therapeutic acid inhibition with PPIs alters the microbiome in the stomach, and the corresponding reflux of this microbiome community into the esophagus may occur. The possible role of the microbiome in the pathogenesis of esophageal diseases still needs to be researched. New approaches in the treatment of mild to moderate forms of GERD aim to strengthen the esophageal mucosal barrier instead of acid inhibition.
Medication Effects on the Gut Microbiome
BioProphyl: Have you gained any insights during your research on how medications like aspirin or NSAIDs could affect the gut microbiome and the barrier function of the gastrointestinal tract?
Prof. Dr. Dr. h.c. Peter Malfertheiner: The damaging effect of aspirin and NSAIDs on the gastric mucosa is exacerbated by an H. pylori infection. Medications that affect the integrity of the gut mucosal barrier, such as NSAIDs, also alter the gut microbiome and are therefore considered unfavorable.
Treating the H. pylori infection is essential in any case. Clinical studies are needed to determine whether and in which patients additional probiotic therapy is advisable.
Future Technologies for Microbiome Therapies
BioProphyl: In your opinion, what are the most promising approaches or technologies for utilizing the gut microbiome in future therapeutic or diagnostic strategies for gastrointestinal diseases?
Prof. Dr. Dr. h.c. Peter Malfertheiner: Initially, it is about the use of diagnostic procedures to meet today's demand for precision medicine. Each segment of the digestive tract represents a specialized niche with adapted microbiome communities. We have been able to gather corresponding findings in both healthy and sick individuals by taking mucosal samples from different sections of the digestive tract during endoscopic examinations and analyzing their microbial composition.
To study the contribution of the microbiome to diseases, it is important to examine the affected sections of the gastrointestinal tract for the specific features of the microbiome located there. In clinical routine, we can rely on stool microbiome analyses, but we must be aware that this currently provides us with limited insight into personalized application in consultation and therapy regarding the microbiome. Many factors influencing the gut microbiome must be considered when evaluating the stool microbiome. Stool and tissue microbiome analyses will undoubtedly be part of our treatment strategies in the future.
For example, the microbiome is altered during diets or even a gluten-free diet. Measures such as additional modulation of the microbiome must be individually evaluated.
Stool transfer or microbiome encapsulated from healthy "microbiome donors" will be used for existing and new treatment indications. Probiotics already have clear indications, and their further development will open new treatment options.
Conclusion: The realization that the microbiome, in its individual composition, is shaped by a healthy lifestyle and diet and plays a crucial role is a new concept that has been increasingly secured and expanded over the last 15 years. Without considering the microbiome, innovative, individualized therapies in the future are, in my opinion, unimaginable.



